Tibulizumab (IL17A/TNFSF13B/CD257) - Onderzoeksgraad Biosimilar
Gecertificeerd

Tibulizumab (IL17A/TNFSF13B/CD257) - Onderzoeksgraad Biosimilar

Catalog #: 10-867
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Immunogen

Humanized / IL17A/TNFSF13B/CD257 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Neuroscience

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG4-kappa-[scFv]2

NCBI Organism

Homo sapiens

Other Product Names

LY 3090106, LY-3090106, LY3090106

Beschrijving

Tibulizumab (IL17A/TNFSF13B/CD257) - Onderzoeksgraad Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamTibulizumab (IL17A/TNFSF13B/CD257) - Onderzoeksgraad Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-867